STOCKS TELEGRAPH

Tag: OpGen Stock

  • Why OpGen (OPGN) Stock Is Skyrocketing Pre-Hours Today?

    Why OpGen (OPGN) Stock Is Skyrocketing Pre-Hours Today?

    OpGen, Inc. (NASDAQ: OPGN) shares are experiencing a remarkable surge during the premarket trading session today, demonstrating a notable increase of 542.86%, with the stock price reaching $2.16. In the preceding trading session, OpGen (OPGN) shares exhibited a modest decline of 2.89%, ultimately concluding the day’s trading at $0.3360.

    The significant upswing in the share price can be attributed to a pair of Securities and Exchange Commission (SEC) filings pertaining to the issuance of preferred shares and an advance payment resulting from a purchase agreement, which have positively impacted the stock’s performance before the market opening.

    In its first disclosure, OpGen unveiled a strategic financial arrangement executed on October 11, 2023. This initiative involved a Preferred Stock Purchase Agreement with a solitary investor, wherein OpGen committed to privately allocate 1,000 shares of the Company’s Series D Preferred Stock at $1,000 per share, generating $1.0 million in gross proceeds. This capital injection was dedicated to sustaining OpGen’s operations and facilitating prospective strategic endeavors with the investor. The anticipated strategic transaction will be governed by a definitive agreement.

    In a separate filing, OpGen’s subsidiary, Curetis GmbH, received a substantial upfront payment of 750,000 euros on October 6, 2023. This payment was associated with the impending sale of Unyvero A50 systems to a strategic partner. The specifics of the final purchase are pending agreement in a purchase order or agreement between the parties.

    This transaction was part of broader negotiations involving Curetis, Ares Genetics GmbH (another OpGen subsidiary), and the strategic partner, with potential for further acquisitions by the partner. The ongoing negotiations will result in a comprehensive agreement. OpGen plans to employ the received advance payment to bolster the operational capabilities of Curetis and Ares Genetics while continuing discussions with the strategic partner.

    Both of these transactions exemplify OpGen’s commitment to fortifying its financial foundation and pursuing strategic growth opportunities in a deliberate and calculated manner.

  • OPGN Stock Is Falling This Morning, On What Basis?

    OPGN Stock Is Falling This Morning, On What Basis?

    On the last check Thursday, OpGen Inc. (OPGN) plunged -4.39% at $2.18 in pre-market trading hours. OpGen’s stock lost -0.87% to close at $2.28 in the last trading session. The price range for the OPGN stock was $2.24 to $2.32. Over the past 100 days, it has traded 6.42 million shares daily on average, which was higher than the OPGN stock volume of 1.34 million on the day. In the last five days, OPGN’s shares fell by -3.39%, while they gained 1.79% in the last month. OPGN stock fell after announcing partial adjournment of the annual meeting.

    The OPGN meeting will take place when?

    To combat infectious diseases, OpGen combines molecular diagnostics with bioinformatics. As a developer and manufacturer of molecular microbiology solutions, OPGN develops solutions in conjunction with subsidiaries, Curetis GmbH and Ares Genetics GmbH. With OPGN’s solutions, clinicians are provided with more rapid and actionable information regarding potentially life-threatening infections, which can lead to better patient outcomes and a decrease in the spread of infections due to multidrug-resistant microorganisms. Unyvero, Acuitas’ AMR Gene Panel, and Acuitas Lighthouse, are part of OPGN’s product offering, as is the ARES Technology Platform, which uses NGS and AI to predict antibiotic response.

    On July 7, 2021, OpGen resumed its partially adjourned 2021 annual stockholders meeting.

    • In its Definitive Proxy Statement dated April 26, 2021, OPGN’s annual meeting was delayed solely due to Proposal 2.
    • The proxy statement was related to an increase in the number of shares of common stock authorized by OPGN.
    • To provide its stockholders with additional time to vote on Proposal 2, OPGN adjourned the Annual Meeting regarding such proposal.
    • Proposal 2 will now be discussed at the Annual Meeting at 10:00 am Eastern time on August 5, 2021.
    • OPGN’s offices at 9717 Key West Ave, Suite 100, Rockville, MD 20850 will continue to host the Annual Meeting.
    • At OPGN’s Annual Meeting, April 5, 2021 will remain the record date for determining who can vote.
    • The recent feedback and dialogue with many stockholders, and the number of stockholders who have already voted in favor of this important proposal, are encouraging to OPGN.
    • The importance of this proposal for the future success of the OPGN cannot be overstated.
    • This proposal is thus unanimously recommended be approved by the OPGN Board.

    Why the proposal is important for OPGN?

    With its strong cash position of $39.4 million at the end of the second quarter of 2021, these additional authorized shares will provide OpGen (OPGN) with the additional flexibility to seek future funding in order to continue expanding, strategically managing and possibly helping to reduce its long-term debt, and raising additional capital when needed. Management and OPGN’s board of directors have determined that, since this proposal requires an affirmative vote of at least 66.67% of all shares outstanding, alternate options must be explored simultaneously to fund the Company’s growth and development.